Showing 1 posts of 1 posts found.
Biogen (NASDAQ: BIIB) has announced the appointment of Dr Michael Ehlers as executive vice president, research and development. His role …
London secures major investment to accelerate healthcare innovation
People with severe mental illness more likely to die early from cardiovascular disease, report finds
Yourgene wins Australian approval for chemotherapy toxicity screening assay
ProBioGen secures extended GMP authorisation for viral manufacturing facility
PlaqueTec coronary disease trial reaches 100 patients across eight NHS centres